- Home
- NMRA vs ESPR Comparison
NMRA vs ESPR Comparison
Compare NMRA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- ESPR
- Stock Information
- Founded
- NMRA 2019
- ESPR 2008
- Country
- NMRA United States
- ESPR United States
- Employees
- NMRA N/A
- ESPR N/A
- Industry
- NMRA
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- ESPR Health Care
- Exchange
- NMRA Nasdaq
- ESPR Nasdaq
- Market Cap
- NMRA 234.5M
- ESPR 220.0M
- IPO Year
- NMRA 2023
- ESPR 2013
- Fundamental
- Price
- NMRA $2.08
- ESPR $1.41
- Analyst Decision
- NMRA Buy
- ESPR Buy
- Analyst Count
- NMRA 8
- ESPR 6
- Target Price
- NMRA $7.14
- ESPR $6.50
- AVG Volume (30 Days)
- NMRA 2.2M
- ESPR 5.1M
- Earning Date
- NMRA 08-06-2025
- ESPR 08-05-2025
- Dividend Yield
- NMRA N/A
- ESPR N/A
- EPS Growth
- NMRA N/A
- ESPR N/A
- EPS
- NMRA N/A
- ESPR N/A
- Revenue
- NMRA N/A
- ESPR $259,574,000.00
- Revenue This Year
- NMRA N/A
- ESPR $6.10
- Revenue Next Year
- NMRA N/A
- ESPR N/A
- P/E Ratio
- NMRA N/A
- ESPR N/A
- Revenue Growth
- NMRA N/A
- ESPR 12.99
- 52 Week Low
- NMRA $0.61
- ESPR $0.69
- 52 Week High
- NMRA $17.19
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NMRA 70.06
- ESPR 59.92
- Support Level
- NMRA $1.70
- ESPR $1.13
- Resistance Level
- NMRA $2.85
- ESPR $1.74
- Average True Range (ATR)
- NMRA 0.32
- ESPR 0.17
- MACD
- NMRA 0.05
- ESPR 0.03
- Stochastic Oscillator
- NMRA 58.08
- ESPR 31.63
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.